New Challenges for Use of Embryonic Stem Cells - - BioPharm International


New Challenges for Use of Embryonic Stem Cells

BioPharm Bulletin

The National Institutes of Health’s (NIH) definition of embryonic stem (ES) cells poses new challenges for investigators who seek federal research funding. Current NIH guidelines narrowly define ES cells, as “cells that are derived from the inner cell mass of blastocyst stage human embryos, are capable of dividing without differentiating for a prolonged period in culture, and are known to develop into cells and tissues of the three primary germ layers" (1). 

More than 75 such cell lines have been approved to receive federal funding for research. A smaller subset of ES cells, however, has been excluded from funding because it does not meet the narrow definition. ES cells can now be derived from a single blastomere taken from an eight-cell embryo, in a procedure similar to that used during genetic testing on embryos created by in vitro fertilization. After the blastomere is removed, the embryo remains viable and is refrozen. Although this procedure does not destroy human embryos, cell lines derived in this fashion are currently awaiting further review by NIH.  

FDA has given Advanced Cell Technology clearance to start clinical trials for macular degeneration this year using cells produced from a blastomere-derived ES cell line. The company was forced to find alternative sources of funding for their trial since their cell line is not eligible to receive federal funds.

In Europe, regulations regarding embryonic stem-cell research differ from country to country. However, a ruling on Mar. 10, 2011, by the European Court of Justice of the European Communities denied patents on ES cells to Oliver Brüstle of the University of Bonn on ethical grounds. The court found that even if cell lines could be established without the destruction of embryos, the commercialization of human embryos was unacceptable, and contrary to public policy. This ruling may push European countries to adopt restrictive policies regarding embryonic stem cells and inhibit the development of ES-based therapies.

(1) National Institutes of Health, “Guidelines for Research Using Human Stem Cells,” (Bethesda, MD, July 2009),

blog comments powered by Disqus



First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm Bulletin,
Click here